Oxaliplatin-Induced Fever and Release of IL-6

Background: Oxaliplatin is a novel cytotoxic agent with documented activity in colorectal cancer. Side effects are generally moderate, and include peripheral neuropathy along with mild bone marrow suppression and gastrointestinal side effects. To our knowledge, induction of febrile episodes by this agents has not been described in the literature. Case Report: We present the case of a 74-year-old male patient admitted to our institution for palliative treatment of metastatic colorectal carcinoma. Due to progression during treatment with 5-fluorouracil and leucovorin, chemotherapy consisting of oxaliplatin 85 mg/m2 on days 1 + 15 plus mitomycin C 8 mg/m2 on day 1 repeated every 28 days was initiated. The first cycle of this combination was tolerated without side effects, but the patient experienced fever up to 39°C starting 2 h after oxaliplatin administration on day 15 of the second cycle, which persisted for 3 days. Fever again recurred at the same interval following administration of oxaliplatin on day 1 of the next cycle. Blood samples taken at regular intervals disclosed an increase in IL-6 serum levels parallel to the body temperature curve, with the peak corresponding to the highest temperature, while C-reactive protein values remained unchanged. In spite of intensive premedication with steroids, antipyretics and clarithromycin, fever promptly recurred during the third cycle of treatment. Conclusion: Our data suggest a clear- cut correlation between fever, the release of IL-6 and oxaliplatin administration. Whether IL-6 release is directly triggered by the application of oxaliplatin or is a bystander phenomenon, however, remains unclear at the moment.

[1]  P. Breton,et al.  Anaphylactic Reaction to Oxaliplatin: A Case Report , 1999, American Journal of Gastroenterology.

[2]  C. Miki,et al.  Serum interleukin‐6 level reflects the tumor proliferative activity in patients with colorectal carcinoma , 1999, Cancer.

[3]  L. Wiseman,et al.  Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. , 1999, Drugs & aging.

[4]  S. Piperno-Neumann,et al.  Anaphylaxis after oxaliplatin. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  W. Scheithauer,et al.  Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Taguchi,et al.  [Phase I clinical study of oxaliplatin]. , 1998, Gan to kagaku ryoho. Cancer & chemotherapy.

[7]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .

[8]  C. Tournigand,et al.  Severe anaphylactic reactions to oxaliplatin. , 1998, European journal of cancer.

[9]  J. Misset Oxaliplatin in practice. , 1998, British Journal of Cancer.

[10]  M. Marty,et al.  Pharmacokinetics and safety profile of oxaliplatin. , 1998, Seminars in oncology.

[11]  Misset Jl Oxaliplatin in practice. , 1998 .

[12]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. , 1998, European journal of cancer.

[13]  E. Raymond,et al.  [Oxaliplatin: the first DACH platinum in clinical practice]. , 1997, Bulletin du cancer.

[14]  G. Welzl,et al.  Regulated plasma levels of colony‐stimulating factors, interleukin‐6 and interleukin‐10 in patients with acute leukaemia and non‐Hodgkin's lymphoma undergoing cytoreductive chemotherapy , 1996, British journal of haematology.

[15]  M. Björkholm,et al.  Monitoring of endotoxin, interleukin‐6 and C‐reactive protein serum concentrations in neutropenic patients with fever , 1995, European journal of haematology.

[16]  S. Steinshamn,et al.  Soluble tumour necrosis factor receptors, tumour necrosis factor and interleukin‐6 in serum in granulocytopenic patients with fever , 1995, British journal of haematology.

[17]  K. Pulkki,et al.  Endotoxin, interleukin-6 and phospholipase-A2 as markers of sepsis in patients with hematological malignancies. , 1995, Scandinavian journal of infectious diseases.

[18]  W. Graninger,et al.  Release of TNF alpha and IL6 from human monocytes infected with Mycobacterium kansasii: a comparison to Mycobacterium avium. , 1994, Infection.

[19]  A. Reinberg,et al.  Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in mice. , 1989, Cancer research.

[20]  C. Kumana,et al.  Fulminant hyperpyrexia induced by bleomycin. , 1989, Postgraduate medical journal.

[21]  G. Jacoby,et al.  Fever of undetermined origin. , 1973, The New England journal of medicine.